Max Planck Society spin-off QLi5 secures multi-million Euro investment from Qurient Therapeutics to advance its cutting-edge Proteasome Inhibitor ADC Platform. This funding will propel the development of a novel, non-covalent proteasome inhibitor payload, offering a universal solution for cancer treatment. With a strong scientific foundation rooted in Nobel Prize-winning research, QLi5 is poised to revolutionize ADC technology and address the limitations of existing therapeutics. The investment, led by Qurient and co-founder Robert Huber, will accelerate the platform's potential, making it a game-changer in the global ADC market.
